Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Carcinogenesis ; 36(12): 1531-8, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26464196

RESUMEN

Chemoprevention provides an important strategy for cancer control in passive smokers. Due to the crucial role played by smoke-related chronic inflammation in lung carcinogenesis, of special interest are extensively used pharmacological agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs). We evaluated the ability of aspirin and naproxen, inhibitors of both cyclooxygenase-1 and cyclooxygenase -2, to modulate environmental cigarette smoke (ECS)-induced lung carcinogenesis in A/J mice of both genders. Based on a subchronic toxicity study in 180 postweaning mice, we used 1600 mg/kg diet aspirin and 320 mg/kg diet naproxen. In the tumor chemoprevention study, using 320 mice, exposure to ECS started soon after birth and administration of NSAIDs started after weaning. At 10 weeks of life, the NSAIDs did not affect the presence of occult blood in feces. As assessed in a subset of 40 mice, bulky DNA adducts and 8-hydroxy-2'-deoxyguanosine levels were considerably increased in ECS-exposed mice and, irrespective of gender, both NSAIDs remarkably inhibited these nucleotide alterations. After exposure for 4 months followed by 5 months in filtered air, ECS induced a significant increase in the yield of surface lung tumors, the 43.7% of which were adenomas and the 56.3% were adenocarcinomas. Oct-4 (octamer-binding transcription factor 4), a marker of cell stemness, was detected in some adenocarcinoma cells. The NAIDs attenuated the yield of lung tumors, but prevention of ECS-induced lung adenomas was statistically significant only in female mice treated with aspirin, which supports a role for estrogens in ECS-related lung carcinogenesis and highlights the antiestrogenic properties of NSAIDs.


Asunto(s)
Anticarcinógenos/farmacología , Aspirina/farmacología , Neoplasias Pulmonares/prevención & control , Naproxeno/farmacología , Contaminación por Humo de Tabaco/efectos adversos , Animales , Anticarcinógenos/uso terapéutico , Aspirina/uso terapéutico , Daño del ADN , Evaluación Preclínica de Medicamentos , Femenino , Pulmón/metabolismo , Pulmón/patología , Neoplasias Pulmonares/etiología , Neoplasias Pulmonares/genética , Masculino , Ratones , Naproxeno/toxicidad , Factor 3 de Transcripción de Unión a Octámeros/metabolismo
2.
Arch Dermatol Res ; 305(1): 25-34, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22699427

RESUMEN

Chemotherapy-induced hair loss is one of the most serious and feared adverse effects of cancer therapy. Almost all traditional chemotherapeutic agents induce a more or less severe alopecia. At present, there is no effective treatment capable of preventing this damage. Several different experimental approaches, using various animal models, have been investigated over the last years, with promising results. Sulphur-containing amino acids (cystine, cysteine) are essential components for the health of normal hair. L-Cystine is used in the treatment of various forms of alopecia. Vitamin B6 plays an important role in the development and maintenance of the skin and it is useful in reducing hair loss. In the present study, we demonstrated that the combined oral administration at high dosages of L-cystine (1,600 or 800 mg/kg body weight/day) and vitamin B6 (160 or 80 mg/kg body weight/day) is an effective chemopreventive treatment against alopecia induced by doxorubicin treatment (1.1 mg/kg body weight intravenously) in C57BL/6 mice.


Asunto(s)
Alopecia/prevención & control , Antibióticos Antineoplásicos , Cisteína/administración & dosificación , Dieta , Doxorrubicina , Cabello/efectos de los fármacos , Vitamina B 6/administración & dosificación , Alopecia/inducido químicamente , Alopecia/patología , Animales , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Cabello/patología , Folículo Piloso/efectos de los fármacos , Folículo Piloso/patología , Ratones , Ratones Endogámicos C57BL , Factores de Tiempo
3.
Int J Cancer ; 131(9): 1991-7, 2012 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-22328465

RESUMEN

Cigarette smoke (CS) and dietary factors play a major role in cancer epidemiology. At the same time, however, the diet is the richest source of anticancer agents. Berries possess a broad array of health protective properties and were found to attenuate the yield of tumors induced by individual carcinogens in the rodent digestive tract and mammary gland but failed to prevent lung tumors induced by typical CS components in mice. We exposed whole-body Swiss ICR mice to mainstream CS, starting at birth and continuing daily for 4 months. Aqueous extracts of black chokeberry and strawberry were given as the only source of drinking water, starting after weaning and continuing for 7 months, thus mimicking an intervention in current smokers. In the absence of berries, CS caused a loss of body weight, induced early cytogenetical damage in circulating erythrocytes and histopathological alterations in lung (emphysema, blood vessel proliferation, alveolar epithelial hyperplasia and adenomas), liver (parenchymal degeneration) and urinary bladder (epithelial hyperplasia). Both berry extracts inhibited the CS-related body weight loss, cytogenetical damage, liver degeneration, pulmonary emphysema and lung adenomas. Protective effects were more pronounced in female mice, which may be ascribed to modulation by berry components of the metabolism of estrogens implicated in lung carcinogenesis. Interestingly, both the carcinogen and the chemopreventive agents tested are complex mixtures that contain a multitude of components working through composite mechanisms.


Asunto(s)
Anticarcinógenos/farmacología , Fragaria/química , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/prevención & control , Photinia/química , Extractos Vegetales/farmacología , Humo/efectos adversos , Animales , Peso Corporal/efectos de los fármacos , Femenino , Hígado/efectos de los fármacos , Hígado/patología , Hepatopatías/prevención & control , Pulmón/efectos de los fármacos , Pulmón/patología , Neoplasias Pulmonares/patología , Masculino , Ratones , Ratones Endogámicos ICR , Nicotiana , Contaminación por Humo de Tabaco/efectos adversos , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/patología
4.
J Dermatol Sci ; 46(3): 189-98, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17374475

RESUMEN

BACKGROUND: We previously demonstrated that high doses of environmental cigarette smoke (ECS) induce alopecia in mice. This effect was prevented by the oral administration of N-acetylcysteine (NAC), an analogue and precursor of L-cysteine and reduced glutathione. OBJECTIVES: The present study aimed at assessing whether L-cystine, the oxidized form of L-cysteine, which is a key hair component, may behave like NAC in inhibiting ECS-induced alopecia and modulating the mechanisms responsible for this condition. METHODS: C57BL/6 mice were exposed whole-body to ECS in a smoking machine. Groups of mice received in the diet, at three dose levels, a mixture of L-cystine with vitamin B6, which plays a role in L-cystine incorporation in hair cells. Occurrence of alopecia areas and apoptosis of hair bulb cells were evaluated for up to 6 months of exposure, and the time course induction of micronucleated erythrocytes in peripheral blood was investigated. RESULTS: The frequency of micronucleated erythrocytes was increased by ECS, irrespective of treatment with L-cystine/vitamin B6. ECS-induced alopecia and apoptosis of hair bulb cells in all exposed mice. L-Cystine/vitamin B6 inhibited alopecia in a dose-dependent fashion. CONCLUSIONS: High-dose ECS induces apoptosis-related alopecia in mice, and oral administration of L-cystine/vitamin B6 is an effective preventive treatment.


Asunto(s)
Alopecia/etiología , Alopecia/prevención & control , Quimioprevención/métodos , Cistina/farmacología , Contaminación por Humo de Tabaco/efectos adversos , Vitamina B 6/farmacología , Acetilcisteína/administración & dosificación , Acetilcisteína/farmacología , Administración Oral , Alopecia/patología , Animales , Apoptosis , Peso Corporal , Cistina/administración & dosificación , Cistina/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Folículo Piloso/metabolismo , Folículo Piloso/patología , Ratones , Ratones Endogámicos C57BL , Vitamina B 6/administración & dosificación
5.
Carcinogenesis ; 23(4): 587-93, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11960910

RESUMEN

Several studies have shown that hexavalent chromium [Cr(VI)] induces apoptosis in a variety of in vitro test systems. We instilled intra-tracheally either saline or sodium dichromate (0.25 mg/kg body weight), for three consecutive days, to Sprague-Dawley rats. TUNEL analyses showed a marked increase of the apoptotic index in both bronchial epithelium and lung parenchyma of Cr(VI)-treated rats, but no effect was detected in their liver. In parallel, the expression of 13 out of 18 apoptosis-related genes, evaluated by cDNA array analysis, was significantly enhanced in rat lung. The overexpressed genes included c-Jun N-terminal kinases 1, 2 and 3, bcl-x, bcl-2-associated death promoter and bcl-2-related ovarian killer protein, caspases 1, 3 and 6, DNase I precursor, DNA topoisomerases I and II alpha, and poly(ADP-ribose) polymerase. The enhancement of p53 expression in the lung was borderline to statistical significance. Expressions of bcl-2, bax-alpha, mdm2 and DNA topoisomerase IIB were not enhanced to a significant extent in lung. No induction of gene expression was observed in rat liver. RT-PCR analyses confirmed that Cr(VI) enhances the expression of c-Jun N-terminal kinase 1, caspase 6, and DNase I precursor but not that of bcl-2 in lung, while none of these genes was overexpressed in the liver of Cr(VI)-treated rats. The lack of stimulation of apoptosis in the liver parallels the failure of Cr(VI) to produce genotoxic damage, as we previously observed under identical experimental conditions. These negative findings may be ascribed to reduction of Cr(VI) to Cr(III) when traveling from the respiratory tract to the liver. On the other hand, induction of apoptosis in the respiratory tract parallels the occurrence of genotoxic effects and oxidative DNA damage produced by Cr(VI) in the same tissue. As previously shown in another laboratory, Cr(VI) did not induce lung tumors after 30 months of administration of the same daily dose. Therefore, apoptosis is likely to provide a protective mechanism at a post-genotoxic stage of Cr(VI) carcinogenesis.


Asunto(s)
Apoptosis , Cromo/administración & dosificación , Cromo/farmacología , Hígado/patología , Pulmón/patología , Proteínas Nucleares , Proteínas Proto-Oncogénicas c-bcl-2 , Animales , Carcinógenos Ambientales , Caspasa 6 , Caspasas/biosíntesis , Cromatos/farmacología , ADN-Topoisomerasas de Tipo II/biosíntesis , ADN Complementario/metabolismo , Proteínas de Unión al ADN , Desoxirribonucleasa I/biosíntesis , Relación Dosis-Respuesta a Droga , Etiquetado Corte-Fin in Situ , Proteínas Quinasas JNK Activadas por Mitógenos , Hígado/efectos de los fármacos , Pulmón/efectos de los fármacos , Masculino , Proteínas Quinasas Activadas por Mitógenos/biosíntesis , Análisis de Secuencia por Matrices de Oligonucleótidos , Proteínas Proto-Oncogénicas/biosíntesis , Proteínas Proto-Oncogénicas c-mdm2 , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Tiempo , Tráquea/metabolismo , Proteína X Asociada a bcl-2
6.
Cancer Epidemiol Biomarkers Prev ; 11(2): 167-75, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11867504

RESUMEN

N-Acetyl-L-cysteine (NAC) has been shown to exert cancer-protective mechanisms and effects in experimental models. We report here the results of a randomized, double-blind, placebo-controlled, Phase II chemoprevention trial with NAC in healthy smoking volunteers. The subjects were supplemented daily with 2 x 600 mg of oral tablets of NAC (n = 20) or placebo (n = 21) for a period of 6 months, and internal dose markers [plasma and bronchoalveolar lavage (BAL) fluid cotinine, urine mutagenicity], biologically effective dose markers [smoking-related DNA adducts and hemoglobin (Hb) adducts], and biological response markers (micronuclei frequency and antioxidants scavenging capacity) were assessed at both pre- and postsupplementation times (T(0) and T(1), respectively). Overall, the internal dose markers remained unchanged at T(1) as compared with T(0) in both NAC and placebo groups. When quantifying the biologically effective dose markers, we observed an inhibitory effect of NAC toward the formation of lipophilic-DNA adducts (5.18 +/- 0.73 versus 4.08 +/- 1.03/10(8) nucleotides; mean +/- SE; P = 0.05) as well as of 7,8-dihydro-8-oxo-2'-deoxyguanosine adducts in BAL cells (3.9 +/- 0.6 versus 2.3 +/- 0.2/10(5) nucleotides; P = 0.003). There was no effect of NAC on the formation of lipophilic-DNA adducts in peripheral blood lymphocytes or polycyclic aromatic hydrocarbon-DNA adducts in mouth floor/buccal mucosa cells or 4-aminobiphenyl-Hb adducts. Likewise, quantification of the biological response markers showed an inhibitory effect of NAC on the frequency of micronuclei in mouth floor and in soft palate cells (1.3 +/- 0.2 versus 0.9 +/- 0.2; P = 0.001) and a stimulating effect of NAC on plasma antioxidant scavenging capacity (393 +/- 14 versus 473 +/- 19 microM Trolox; P = 0.1) but not on BAL fluid antioxidant scavenging capacity. We conclude that NAC has the potential to impact upon tobacco smoke carcinogenicity in humans because it can modulate certain cancer-associated biomarkers in specific organs.


Asunto(s)
Acetilcisteína/uso terapéutico , Anticarcinógenos/uso terapéutico , Antioxidantes/uso terapéutico , Depuradores de Radicales Libres/uso terapéutico , Neoplasias/prevención & control , Fumar/metabolismo , Acetilcisteína/administración & dosificación , Administración Oral , Adulto , Anticarcinógenos/administración & dosificación , Antioxidantes/administración & dosificación , Biomarcadores/análisis , Cotinina/metabolismo , Aductos de ADN , Daño del ADN , Método Doble Ciego , Femenino , Depuradores de Radicales Libres/administración & dosificación , Humanos , Masculino , Pruebas de Mutagenicidad , Neoplasias/etiología , Fumar/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA